ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,304.72
      0.70%
      US Tech 100
      18,317.60
      0.94%
      Dow Jones
      39,069.59
      0.01%
      Brent Oil
      81.965
      0.81%
      Bitcoin
      68,765.76
      1.24%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Regulus Therapeutics Inc (RGLS)

      7. Regulus Therapeutics Inc (RGLS) News

      RGLS

      Regulus Therapeutics (RGLS)

      Regulus Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:RGLS
      DateTimeSourceHeadlineSymbolCompany
      05/21/20244:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      05/21/20244:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      05/21/20244:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      05/21/20244:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      05/21/20244:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      05/21/20244:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      05/20/20244:11PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGLSRegulus Therapeutics Inc
      05/17/20245:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      05/17/20244:44PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      05/17/20244:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      05/17/20244:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      05/17/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
      05/16/20248:00AMPR Newswire (US)Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerNASDAQ:RGLSRegulus Therapeutics Inc
      05/09/20244:54PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RGLSRegulus Therapeutics Inc
      05/09/20244:27PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGLSRegulus Therapeutics Inc
      05/09/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
      05/09/20244:05PMPR Newswire (US)Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
      05/06/20248:00AMPR Newswire (US)Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
      04/30/20248:00AMPR Newswire (US)Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesNASDAQ:RGLSRegulus Therapeutics Inc
      03/21/20244:05PMPR Newswire (US)Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
      03/12/20246:32AMPR Newswire (US)Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of EquityNASDAQ:RGLSRegulus Therapeutics Inc
      03/12/20246:30AMPR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
      01/18/20248:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      01/18/20248:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      01/17/20245:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      01/17/20245:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
      01/12/20244:11PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGLSRegulus Therapeutics Inc
      01/10/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RGLSRegulus Therapeutics Inc
      01/02/20244:05PMPR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
      12/27/20234:16PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RGLSRegulus Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:RGLS